Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Article Details
- CitationCopy to clipboard
Wu J, Zhang M, Liu D
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.
- PubMed ID
- 26957112 [ View in PubMed]
- Abstract
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.